We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cash-rich Johnson & Johnson (J&J) is ready to take advantage of opportunities this year to purchase pharmaceutical or life science assets at distressed prices, but the company is not interested in biosimilars.